@article{MTMT:34530314,
	title = {Persistently High Procalcitonin and C-Reactive Protein Are Good Predictors of Infection in Acute Necrotizing Pancreatitis: A Systematic Review and Meta-Analysis},
	url = {https://m2.mtmt.hu/api/publication/34530314},
	author = {Tarján, Dorottya and Szalai, Eszter and Lipp, Mónika Bernadett and Verbói, Máté and Kói, Tamás and Erőss, Bálint Mihály and Teutsch, Brigitta and Faluhelyi, Nándor and Hegyi, Péter and Mikó, Alexandra},
	doi = {10.3390/ijms25021273},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {25},
	unique-id = {34530314},
	issn = {1661-6596},
	abstract = {Infected necrotizing pancreatitis (INP) is associated with an increased risk of organ failure and mortality. Its early recognition and timely initiation of antibiotic therapy can save patients’ lives. We systematically searched three databases on 27 October 2022. In the eligible studies, the presence of infection in necrotizing pancreatitis was confirmed via a reference test, which involved either the identification of gas within the necrotic collection through computed tomography imaging or the examination of collected samples, which yielded positive results in Gram staining or culture. Laboratory biomarkers compared between sterile necrotizing pancreatitis and INP were used as the index test, and our outcome measures included sensitivity, specificity, the receiver operating characteristic (ROC) curve and area under the ROC curve (AUC). Within the first 72 hours (h) after admission, the AUC of C-reactive protein (CRP) was 0.69 (confidence interval (CI): 0.62–0.76), for procalcitonin (PCT), it was 0.69 (CI: 0.60–0.78), and for white blood cell count, it was 0.61 (CI: 0.47–0.75). After the first 72 h, the pooled AUC of CRP showed an elevated level of 0.88 (CI: 0.75–1.00), and for PCT, it was 0.86 (CI: 0.60–1.11). The predictive value of CRP and PCT for infection is poor within 72 h after hospital admission but seems good after the first 72 h. Based on these results, infection is likely in case of persistently high CRP and PCT, and antibiotic initiation may be recommended.},
	year = {2024},
	eissn = {1422-0067},
	orcid-numbers = {Erőss, Bálint Mihály/0000-0003-3658-8427; Teutsch, Brigitta/0000-0002-9530-7886; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:34434496,
	title = {Discharge protocol in acute pancreatitis: an international survey and cohort analysis},
	url = {https://m2.mtmt.hu/api/publication/34434496},
	author = {Nagy, Rita and Ocskay, Klementina and Sipos, Zoltán and Szentesi, Andrea Ildikó and Vincze, Áron and Czakó, László and Izbéki, Ferenc and Shirinskaya, Natalia V and Poluektov, Vladimir L and Zolotov, Alexandr N and Zhu, Yin and Xia, Liang and He, Wenhua and Sutton, Robert and Szatmary, Peter and Mukherjee, Rajarshi and Burridge, Isobel Saffron and Wauchope, Emma and Francisco, Elsa and Aparicio, David and Pinto, Bruno and Gomes, António and Nunes, Vitor and Tantau, Vasile Marcel and Sagau, Emanuela Denisa and Tantau, Alina Ioana and Suceveanu, Andra Iulia and Tocia, Cristina and Dumitru, Andrei and Pando, Elizabeth and Alberti, Piero and Cirera, Arturo and Molero, Xavier and Lee, Hong Sik and Jung, Min Kyu and Kim, Eui Joo and Lee, Sanghyub and Rebollo, María Lourdes Ruiz and Nistal, Reyes Busta and Santervas, Sandra Izquierdo and Lesko, Dusan and Soltes, Marek and Radonak, Jozef and Zatorski, Hubert and Małecka-Panas, Ewa and Fabisiak, Adam and Yaroslav, M Susak and Mykhailo, V Maksymenko and Olekcandr, A Tkachenko and Barauskas, Giedrius and Simanaitis, Vytautas and Ignatavicius, Povilas and Jinga, Mariana and Balaban, Vasile-Daniel and Patoni, Cristina and Gong, Liang and Song, Kai and Li, Yunlong and Gonçalves, T Cúrdia and Freitas, Marta and Macedo, Vítor and Vornhuelz, Marlies and Klauss, Sarah and Beyer, Georg and Koksal, Aydin Seref and Tozlu, Mukaddes and Eminler, Ahmet Tarik and Monclús, Nuria Torres and Comas, Eva Pijoan and Oballe, Juan Armando Rodriguez and Nawacki, Łukasz and Głuszek, Stanisław and Rama-Fernández, Alberto and Galego, Marco and de la Iglesia, Daniel and Aykut, Umut Emre and Duman, Deniz Güney and Aslan, Rahmi and Gherbon, Adriana and Deng, Lihui and Huang, Wei and Xia, Qing and Poropat, Goran and Radovan, Anja and Vranić, Luka and Ricci, Claudio and Ingaldi, Carlo and Casadei, Riccardo and Negoi, Ionut and Ciubotaru, Cezar and Iordache, Florin Mihail and Constantinescu, Gabriel and Sandru, Vasile and Altintas, Engin and Balci, Hatice Rizaoglu and Constantino, Júlio and Aveiro, Débora and Pereira, Jorge and Gunay, Suleyman and Misirlioglu Sucan, Seda and Dronov, Oleksiy and Kovalska, Inna and Bush, Nikhil and Rana, Surinder Singh and Chooklin, Serge and Chuklin, Serhii and Saizu, Ionut Adrian and Gheorghe, Cristian and Göltl, Philipp and Hirth, Michael and Mateescu, Radu Bogdan and Papuc, Geanina and Minkov, Georgi Angelov and Enchev, Emil Tihomirov and Mastrangelo, Laura and Jovine, Elio and Chen, Weiwei and Zhu, Quping and Gąsiorowska, Anita and Fabisiak, Natalia and Bezmarevic, Mihailo and Litvin, Andrey and Mottes, Martina Cattani and Choi, Eun Kwang and Bánovčin, Peter and Nosáková, Lenka and Kovacheva-Slavova, Mila Dimitrova and Kchaou, Ali and Tlili, Ahmed and Marino, Marco V and Kusnierz, Katarzyna and Mickevicius, Artautas and Hollenbach, Marcus and Molcan, Pavol and Ioannidis, Orestis and Tokarev, Mark Valerievich and Ince, Ali Tüzün and Semenenko, Ivan Albertovich and Galeev, Shamil and Ramírez-Maldonado, Elena and Sallinen, Ville and Pencik, Petr and Bajor, Judit and Sarlós, Patrícia and Hágendorn, Roland and Gódi, Szilárd and Szabó, Imre and Czimmer, József and Pár, Gabriella and Illés, Anita and Faluhelyi, Nándor and Kanizsai, Péter László and Nagy, Tamás and Mikó, Alexandra and Németh, Balázs and Hamvas, József and Bod, Barnabás and Varga, Márta and Török, Imola and Novák, János and Patai, Árpád and Sümegi, János and Góg, Csaba and Papp, Mária and Erőss, Bálint Mihály and Váncsa, Szilárd and Teutsch, Brigitta and Márta, Katalin and Hegyi, Péter Jenő and Tornai, Tamás and Lázár, Balázs and Hussein, Tamás and Tarján, Dorottya and Lipp, Mónika Bernadett and Kovács, Beáta and Urbán, Orsolya and Fürst, Emese Rita and Tari, Edina and Kocsis, Ibolya and Maurovich-Horvat, Pál and Tihanyi, Balázs and Eperjesi, Orsolya and Kormos, Zita and Deák, Pál Ákos and Párniczky, Andrea and Hegyi, Péter},
	doi = {10.1038/s41598-023-48480-z},
	journal-iso = {SCI REP},
	journal = {SCIENTIFIC REPORTS},
	volume = {13},
	unique-id = {34434496},
	issn = {2045-2322},
	abstract = {There are several overlapping clinical practice guidelines in acute pancreatitis (AP), however, none of them contains suggestions on patient discharge. The Hungarian Pancreatic Study Group (HPSG) has recently developed a laboratory data and symptom-based discharge protocol which needs to be validated. (1) A survey was conducted involving all members of the International Association of Pancreatology (IAP) to understand the characteristics of international discharge protocols. (2) We investigated the safety and effectiveness of the HPSG-discharge protocol. According to our international survey, 87.5% (49/56) of the centres had no discharge protocol. Patients discharged based on protocols have a significantly shorter median length of hospitalization (LOH) (7 (5;10) days vs. 8 (5;12) days) p < 0.001), and a lower rate of readmission due to recurrent AP episodes (p = 0.005). There was no difference in median discharge CRP level among the international cohorts (p = 0.586). HPSG-protocol resulted in the shortest LOH (6 (5;9) days) and highest median CRP (35.40 (13.78; 68.40) mg/l). Safety was confirmed by the low rate of readmittance (n = 35; 5%). Discharge protocol is necessary in AP. The discharge protocol used in this study is the first clinically proven protocol. Developing and testifying further protocols are needed to better standardize patients' care.},
	year = {2023},
	eissn = {2045-2322},
	orcid-numbers = {Nagy, Rita/0000-0002-2663-4912; Ocskay, Klementina/0000-0001-5848-2506; Sipos, Zoltán/0000-0001-7845-8116; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Vincze, Áron/0000-0003-2217-7686; Czakó, László/0000-0002-6331-0802; Izbéki, Ferenc/0000-0001-7767-4319; Sarlós, Patrícia/0000-0002-5086-9455; Czimmer, József/0000-0001-7831-3523; Kanizsai, Péter László/0000-0001-7896-2857; Nagy, Tamás/0000-0001-5437-1411; Németh, Balázs/0000-0001-5338-7577; Papp, Mária/0000-0003-3662-4010; Erőss, Bálint Mihály/0000-0003-3658-8427; Váncsa, Szilárd/0000-0002-9347-8163; Teutsch, Brigitta/0000-0002-9530-7886; Márta, Katalin/0000-0002-2213-4865; Tari, Edina/0000-0002-8540-0614; Kocsis, Ibolya/0000-0003-3128-2832; Maurovich-Horvat, Pál/0000-0003-0885-736X; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:34211988,
	title = {Fatty Pancreas Is a Risk Factor for Pancreatic Cancer: A Systematic Review and Meta-Analysis of 2956 Patients},
	url = {https://m2.mtmt.hu/api/publication/34211988},
	author = {Lipp, Mónika Bernadett and Tarján, Dorottya and Lee, Jimin and Zolcsák, Ádám and Szalai, Eszter and Teutsch, Brigitta and Faluhelyi, Nándor and Erőss, Bálint Mihály and Hegyi, Péter and Mikó, Alexandra},
	doi = {10.3390/cancers15194876},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {15},
	unique-id = {34211988},
	abstract = {Pancreatic cancer (PC) is one of the most lethal cancers worldwide. Recently, fatty pancreas (FP) has been studied thoroughly, and although its relationship to PC is not fully understood, FP is suspected to contribute to the development of PC. We aimed to assess the association between PC and FP by conducting a systematic review and meta-analysis. We systematically searched three databases, MEDLINE, Embase, and CENTRAL, on 21 October 2022. Case-control and cross-sectional studies reporting on patients where the intra-pancreatic fat deposition was determined by modern radiology or histology were included. As main outcome parameters, FP in patients with and without PC and PC in patients with and without FP were measured. Proportion and odds ratio (OR) with a 95% confidence interval (CI) were used for effect size measure. PC among patients with FP was 32% (OR 1.32; 95% CI 0.42-4.16). However, the probability of having FP among patients with PC was more than six times higher (OR 6.13; 95% CI 2.61-14.42) than in patients without PC, whereas the proportion of FP among patients with PC was 0.62 (95% CI 0.42-0.79). Patients identified with FP are at risk of developing PC. Proper screening and follow-up of patients with FP may be recommended.},
	keywords = {Risk Factors; OBESITY; metabolic syndrome; pancreatic adenocarcinoma; Pancreatic steatosis},
	year = {2023},
	eissn = {2072-6694},
	orcid-numbers = {Zolcsák, Ádám/0000-0002-9128-4867; Teutsch, Brigitta/0000-0002-9530-7886; Erőss, Bálint Mihály/0000-0003-3658-8427; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:33761635,
	title = {Metabolic-associated fatty liver disease is associated with acute pancreatitis with more severe course : Post hoc analysis of a prospectively collected international registry},
	url = {https://m2.mtmt.hu/api/publication/33761635},
	author = {Váncsa, Szilárd and Sipos, Zoltán and Váradi, Alex and Nagy, Rita and Ocskay, Klementina and Juhász, Márk Félix and Márta, Katalin and Teutsch, Brigitta and Mikó, Alexandra and Hegyi, Péter Jenő and Vincze, Áron and Izbéki, Ferenc and Czakó, László and Papp, Mária and Hamvas, József and Varga, Márta and Török, Imola and Mickevicius, Artautas and Erőss, Bálint Mihály and Párniczky, Andrea and Szentesi, Andrea Ildikó and Pár, Gabriella and Hegyi, Péter},
	doi = {10.1002/ueg2.12389},
	journal-iso = {UEG JOURNAL},
	journal = {UNITED EUROPEAN GASTROENTEROLOGY JOURNAL},
	volume = {11},
	unique-id = {33761635},
	issn = {2050-6406},
	abstract = {Non-alcoholic fatty liver disease (NAFLD) is a proven risk factor for acute pancreatitis (AP). However, NAFLD has recently been redefined as metabolic-associated fatty liver disease (MAFLD). In this post hoc analysis, we quantified the effect of MAFLD on the outcomes of AP.We identified our patients from the multicentric, prospective International Acute Pancreatitis Registry of the Hungarian Pancreatic Study Group. Next, we compared AP patients with and without MAFLD and the individual components of MAFLD regarding in-hospital mortality and AP severity based on the revised Atlanta classification. Lastly, we calculated odds ratios (ORs) with 95% confidence intervals (CIs) using multivariate logistic regression analysis.MAFLD had a high prevalence in AP, 39% (801/2053). MAFLD increased the odds of moderate-to-severe AP (OR = 1.43, CI: 1.09-1.89). However, the odds of in-hospital mortality (OR = 0.89, CI: 0.42-1.89) and severe AP (OR = 1.70, CI: 0.97-3.01) were not higher in the MAFLD group. Out of the three diagnostic criteria of MAFLD, the highest odds of severe AP was in the group based on metabolic risk abnormalities (OR = 2.68, CI: 1.39-5.09). In addition, the presence of one, two, and three diagnostic criteria dose-dependently increased the odds of moderate-to-severe AP (OR = 1.23, CI: 0.88-1.70, OR = 1.38, CI: 0.93-2.04, and OR = 3.04, CI: 1.63-5.70, respectively) and severe AP (OR = 1.13, CI: 0.54-2.27, OR = 2.08, CI: 0.97-4.35, and OR = 4.76, CI: 1.50-15.4, respectively). Furthermore, in patients with alcohol abuse and aged ≥60 years, the effect of MAFLD became insignificant.MAFLD is associated with AP severity, which varies based on the components of its diagnostic criteria. Furthermore, MAFLD shows a dose-dependent effect on the outcomes of AP.},
	keywords = {MORTALITY; Prognosis; metabolic syndrome; SEVERITY; Acute pancreatitis; STEATOSIS; Non-Alcoholic Fatty Liver Disease; NAFLD; MAFLD; Metabolic-associated fatty liver disease},
	year = {2023},
	eissn = {2050-6414},
	pages = {371-382},
	orcid-numbers = {Váncsa, Szilárd/0000-0002-9347-8163; Sipos, Zoltán/0000-0001-7845-8116; Váradi, Alex/0000-0001-8229-6340; Nagy, Rita/0000-0002-2663-4912; Ocskay, Klementina/0000-0001-5848-2506; Márta, Katalin/0000-0002-2213-4865; Teutsch, Brigitta/0000-0002-9530-7886; Vincze, Áron/0000-0003-2217-7686; Izbéki, Ferenc/0000-0001-7767-4319; Czakó, László/0000-0002-6331-0802; Papp, Mária/0000-0003-3662-4010; Erőss, Bálint Mihály/0000-0003-3658-8427; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Hegyi, Péter/0000-0003-0399-7259; Imrei, Marcell/0000-0003-0175-7462; Németh, Balázs/0000-0001-5338-7577; Maurovich-Horvat, Pál/0000-0003-0885-736X; Doros, Attila/0000-0002-6496-9895; Zubek, László/0000-0003-0583-3290; Gál, János/0000-0001-9160-6478; Tari, Edina/0000-0002-8540-0614}
}

@article{MTMT:33636629,
	title = {Suprapapillary Biliary Stents Have Longer Patency Times than Transpapillary Stents-A Systematic Review and Meta-Analysis.},
	url = {https://m2.mtmt.hu/api/publication/33636629},
	author = {Kovács, Norbert and Pécsi, Dániel and Sipos, Zoltán and Borbásné Farkas, Kornélia and Földi, Mária and Hegyi, Péter and Bajor, Judit and Erőss, Bálint Mihály and Márta, Katalin and Mikó, Alexandra and Rakonczay, Zoltán and Sarlós, Patrícia and Ábrahám, Szabolcs and Vincze, Áron},
	doi = {10.3390/jcm12030898},
	journal-iso = {J CLIN MED},
	journal = {JOURNAL OF CLINICAL MEDICINE},
	volume = {12},
	unique-id = {33636629},
	abstract = {Endoscopic biliary stent placement is a minimally invasive intervention for patients with biliary strictures. Stent patency and function time are crucial factors. Suprapapillary versus transpapillary stent positioning may contribute to stent function time, so a meta-analysis was performed in this comparison.A comprehensive literature search was conducted in the CENTRAL, Embase, and MEDLINE databases to find data on suprapapillary stent placement compared to the transpapillary method via endoscopic retrograde cholangiopancreatography in cases of biliary stenosis of any etiology and any stent type until December 2020. We carried out a meta-analysis focusing on the following outcomes: stent patency, stent migration, rate of cholangitis and pancreatitis, and other reported complications.Three prospective and ten retrospective studies involving 1028 patients were included. Suprapapillary stent placement appeared to be superior to transpapillary stent positioning in patency (weighted mean difference = 50.23 days, 95% CI: 8.56, 91.98; p = 0.0.018). In a subgroup analysis of malignant indications, suprapapillary positioning showed a lower rate of cholangitis (OR: 0.34, 95% CI: 0.13, 0.93; p = 0.036). Another subgroup analysis investigating metal stents in a suprapapillary position resulted in a lower rate of pancreatitis (OR: 0.16, 95% CI: 0.03, 0.95; p = 0.043) compared to transpapillary stent placement. There was no difference in stent migration rates between the two groups (OR: 0.67, 95% CI: 0.17, 2.72; p = 0.577).Based on our results, suprapapillary biliary stenting has longer stent patency. Moreover, the stent migration rate did not differ between the suprapapillary and transpapillary groups.},
	keywords = {endoscopy; Stent; ERCP; intraductal; inside},
	year = {2023},
	eissn = {2077-0383},
	orcid-numbers = {Pécsi, Dániel/0000-0003-0499-6004; Sipos, Zoltán/0000-0001-7845-8116; Borbásné Farkas, Kornélia/0000-0002-5349-6527; Hegyi, Péter/0000-0003-0399-7259; Erőss, Bálint Mihály/0000-0003-3658-8427; Márta, Katalin/0000-0002-2213-4865; Rakonczay, Zoltán/0000-0002-1499-3416; Sarlós, Patrícia/0000-0002-5086-9455; Ábrahám, Szabolcs/0000-0002-2191-1714; Vincze, Áron/0000-0003-2217-7686}
}

@article{MTMT:32849790,
	title = {In-Hospital Patient Education Markedly Reduces Alcohol Consumption after Alcohol-Induced Acute Pancreatitis.},
	url = {https://m2.mtmt.hu/api/publication/32849790},
	author = {Nagy, Rita and Ocskay, Klementina and Váradi, Alex and Papp, Mária and Vitális, Zsuzsanna and Izbéki, Ferenc and Boros, Eszter and Gajdán, László and Szentesi, Andrea Ildikó and Erőss, Bálint Mihály and Hegyi, Péter Jenő and Vincze, Áron and Bajor, Judit and Sarlós, Patrícia and Mikó, Alexandra and Márta, Katalin and Pécsi, Dániel and Párniczky, Andrea and Hegyi, Péter},
	doi = {10.3390/nu14102131},
	journal-iso = {NUTRIENTS},
	journal = {NUTRIENTS},
	volume = {14},
	unique-id = {32849790},
	abstract = {Although excessive alcohol consumption is by far the most frequent cause of recurrent acute pancreatitis (AP) cases, specific therapy is still not well established to prevent recurrence. Generally, psychological therapy (e.g., brief intervention (BI)) is the cornerstone of cessation programs; however, it is not yet widely used in everyday practice. We conducted a post-hoc analysis of a prospectively collected database. Patients suffering from alcohol-induced AP between 2016 and 2021 received 30 min BI by a physician. Patient-reported alcohol consumption, serum gamma-glutamyl-transferase (GGT) level, and mean corpuscular volume (MCV) of red blood cells were collected on admission and at the 1-month follow-up visit to monitor patients' drinking habits. Ninety-nine patients with alcohol-induced AP were enrolled in the study (mean age: 50 ± 11, 89% male). A significant decrease was detected both in mean GGT value (294 ± 251 U/L vs. 103 ± 113 U/L, p < 0.001) and in MCV level (93.7 ± 5.3 U/L vs. 92.1 ± 5.1 U/L, p < 0.001) in patients with elevated on-admission GGT levels. Notably, 79% of the patients (78/99) reported alcohol abstinence at the 1-month control visit. Brief intervention is an effective tool to reduce alcohol consumption and to prevent recurrent AP. Longitudinal randomized clinical studies are needed to identify the adequate structure and frequency of BIs in alcohol-induced AP.},
	keywords = {Recurrence; ALCOHOL; Acute pancreatitis; Brief intervention; gamma-glutamyl transferase},
	year = {2022},
	eissn = {2072-6643},
	orcid-numbers = {Nagy, Rita/0000-0002-2663-4912; Ocskay, Klementina/0000-0001-5848-2506; Váradi, Alex/0000-0001-8229-6340; Papp, Mária/0000-0003-3662-4010; Vitális, Zsuzsanna/0000-0001-8198-5312; Szentesi, Andrea Ildikó/0000-0003-2097-6927; Erőss, Bálint Mihály/0000-0003-3658-8427; Vincze, Áron/0000-0003-2217-7686; Sarlós, Patrícia/0000-0002-5086-9455; Márta, Katalin/0000-0002-2213-4865; Pécsi, Dániel/0000-0003-0499-6004; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:32614446,
	title = {Exosomes as prognostic biomarkers in pancreatic ductal adenocarcinoma—a systematic review and meta-analysis},
	url = {https://m2.mtmt.hu/api/publication/32614446},
	author = {Bunduc, Stefania and Gede, Noémi and Váncsa, Szilárd and Lillik, Veronika and Kiss, Szabolcs and Juhász, Márk Félix and Erőss, Bálint Mihály and Szakács, Zsolt and Gheorghe, Cristian and Mikó, Alexandra and Hegyi, Péter},
	doi = {10.1016/j.trsl.2022.01.001},
	journal-iso = {TRANSL RES},
	journal = {TRANSLATIONAL RESEARCH},
	volume = {244},
	unique-id = {32614446},
	issn = {1931-5244},
	abstract = {Extensive research is focused on the role of liquid biopsy in pancreatic cancer since reliable diagnostic and follow-up biomarkers represent an unmet need for this highly lethal malignancy. We performed a systematic review and meta-analysis on the prognostic value of exosomal biomarkers in pancreatic ductal adenocarcinoma (PDAC). MEDLINE, Embase, Scopus, Web of Science, and CENTRAL were systematically searched on the 18th of January, 2021 for studies reporting on the differences in overall (OS) and progression-free survival (PFS) in PDAC patients with positive versus negative exosomal biomarkers isolated from blood. The random-effects model estimated pooled multivariate-adjusted (AHR) and univariate hazard ratios (UHRs) with 95% confidence intervals (CIs). Eleven studies comprising 634 patients were eligible for meta-analysis. Detection of positive exosomal biomarkers indicated increased risk of mortality (UHR=2.81, CI:1.31-6,00, I2=88.7%, p<0.001), and progression (UHR=3.33, CI: 2.33-4.77, I2=0, p=0.879) across various disease stages. Positive exosomal biomarkers identified preoperatively revealed a higher risk of mortality in resectable stages (UHR=5.55, CI: 3.24-9.49, I2=0, p=0.898). The risk of mortality in unresectable stages was not significantly increased with positive exosomal biomarkers (UHR=2.51, CI: 0.55-11.43, I2=90.3%, p<0.001). Detectable exosomal micro ribonucleic acids were associated with a decreased OS (UHR=4.08, CI: 2.16-7.69, I2=46.9%, p=0.152) across various stages. Our results reflect the potential of exosomal biomarkers for prognosis evaluation in PDAC. The associated heterogeneity reflects the variability of study methods and need for their uniformization before transition to clinical use.},
	keywords = {Prognosis; Exosomes; Pancreatic ductal adenocarcinoma; liquid biopsy; PDAC},
	year = {2022},
	eissn = {1878-1810},
	pages = {126-136},
	orcid-numbers = {Váncsa, Szilárd/0000-0002-9347-8163; Erőss, Bálint Mihály/0000-0003-3658-8427; Szakács, Zsolt/0000-0002-7035-941X; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:32514829,
	title = {Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta–analysis},
	url = {https://m2.mtmt.hu/api/publication/32514829},
	author = {Bunduc, Stefania and Gede, Noémi and Váncsa, Szilárd and Lillik, Veronika and Kiss, Szabolcs and Dembrovszky, Fanni and Erőss, Bálint Mihály and Szakács, Zsolt and Gheorghe, Cristian and Mikó, Alexandra and Hegyi, Péter},
	doi = {10.1016/j.critrevonc.2021.103548},
	journal-iso = {CRIT REV ONCOL HEMAT},
	journal = {CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY},
	volume = {169},
	unique-id = {32514829},
	issn = {1040-8428},
	abstract = {This systematic review and meta-analysis evaluated the prognostic role of cell-free DNA (cfDNA) in pancreatic ductal adenocarcinoma (PDAC). Eligible studies reported differences in overall (OS) and progression-free survival (PFS) by cfDNA status. The random effect model yielded the pooled hazard ratios (HRs) and 95 % confidence intervals (CI). Detection of circulant-tumor DNA (ctDNA), KRAS mutations and other cfDNA alterations constitute detectable cfDNA biomarkers. Altogether, 38 studies (3,318 patients) were eligible. Progression-free and overall survival were decreased with detectable ctDNA (HR = 1.92, 95 %CI:(1.29,2.86);HR = 2.25, 95 %CI:(1.73,2.92)) and KRAS mutations (HR = 1.88, CI:1.22,2.92,);HR = 1.52, 95 %CI:(1.22, 1.90)) respectively, across various stages. In unresectable cases, ctDNA (HR = 2.50, 95 %CI:(1.94,3.23)), but not KRAS mutations (HR = 1.16, 95 %CI:(0.46,2.94)) signaled risk for progression. Detectable cfDNA biomarkers correlated with worse prognosis in resectable cases and if detected during treatment. In conclusion, cfDNA biomarkers indicate accelerated progression and decreased survival in PDAC. Significance of KRAS mutations detection in unresectable cases is to be determined.},
	keywords = {SURVIVAL; Prognosis; Pancreatic cancer; CELL-FREE DNA; liquid biopsy; pancreatic adenocarcinoma},
	year = {2022},
	eissn = {1879-0461},
	orcid-numbers = {Váncsa, Szilárd/0000-0002-9347-8163; Dembrovszky, Fanni/0000-0001-6953-3591; Erőss, Bálint Mihály/0000-0003-3658-8427; Szakács, Zsolt/0000-0002-7035-941X; Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:32501308,
	title = {The hyperthermic effect of central cholecystokinin is mediated by the cyclooxygenase-2 pathway},
	url = {https://m2.mtmt.hu/api/publication/32501308},
	author = {Kéringer, Patrik and Füredi, Nóra and Gaszner, Balázs and Mikó, Alexandra and Pákai, Eszter and Fekete, Kata and Pótóné Oláh, Emőke and Kelava, Leonardo and Romanovsky, Andrej A and Rumbus, Zoltán and Garami, András},
	doi = {10.1152/ajpendo.00223.2021},
	journal-iso = {AM J PHYSIOL ENDOC M},
	journal = {AMERICAN JOURNAL OF PHYSIOLOGY: ENDOCRINOLOGY AND METABOLISM},
	volume = {322},
	unique-id = {32501308},
	issn = {0193-1849},
	year = {2022},
	eissn = {1522-1555},
	pages = {E10-E23},
	orcid-numbers = {Gaszner, Balázs/0000-0003-2830-2732; Garami, András/0000-0003-2493-0571}
}

@{MTMT:32639846,
	title = {Meta analysis: Prognostic role of cell-free DNA in pancreatic adenocarcinoma},
	url = {https://m2.mtmt.hu/api/publication/32639846},
	author = {Lillik, Veronika and Stefania, Bunduc and Váncsa, Szilárd and Mikó, Alexandra},
	booktitle = {10th Jubilee Interdisciplinary Doctoral Conference : Book of Abstracts = 10. Jubileumi Interdiszciplináris Doktorandusz Konferencia : Absztraktkötet},
	unique-id = {32639846},
	year = {2021},
	pages = {28-28},
	orcid-numbers = {Váncsa, Szilárd/0000-0002-9347-8163}
}